Pharmacological characterizations of the 'legal high' fluorolintane and isomers.

Animals Binding Sites Dose-Response Relationship, Drug Excitatory Postsynaptic Potentials / drug effects Hippocampus / drug effects Isomerism Long-Term Potentiation / drug effects Male Pyrrolidines / chemistry Rats Receptors, N-Methyl-D-Aspartate / metabolism
Diphenidine Fluorolintane Ketamine Legal high NMDA receptor antagonist

Journal

European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354

Informations de publication

Date de publication:
15 Aug 2019
Historique:
received: 05 09 2018
revised: 27 05 2019
accepted: 28 05 2019
pubmed: 4 6 2019
medline: 15 1 2020
entrez: 2 6 2019
Statut: ppublish

Résumé

1,2-Diarylethylamines represent a class of molecules that have shown potential in the treatment of pain, epilepsy, neurodegenerative disease and depression. Examples include lefetamine, remacemide, and lanicemine. Recently, several 1,2-diarylethylamines including the dissociatives diphenidine, methoxphenidine and ephenidine as well as the opioid MT-45, have appeared as 'research chemicals' or 'legal highs'. Due to their recent emergence little is known about their pharmacology. One of these, 1-[1-(2-fluorophenyl)-2-phenylethyl]pyrrolidine (fluorolintane, 2-F-DPPy), is available for purchase with purported dissociative effects intended to resemble phencyclidine (PCP) and ketamine. To better understand this emerging class, pharmacological investigations were undertaken for the first time on fluorolintane and its five aryl-fluorine-substituted isomers. In vitro binding studies revealed high affinity for N-methyl-D-aspartate (NMDA) receptors with fluorolintane (K

Identifiants

DOI: 10.1016/j.ejphar.2019.172427 PMID: 31152702 PMC: PMC6899220
pubmed: 31152702
pii: S0014-2999(19)30378-4
doi: 10.1016/j.ejphar.2019.172427
pmc: PMC6899220
mid: NIHMS1053817
pii:
doi:

Substances chimiques

Pyrrolidines 0
Receptors, N-Methyl-D-Aspartate 0
fluorolintane 0
pyrrolidine LJU5627FYV

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

172427

Subventions

Organisme : Medical Research Council
ID : MR/R010919/1
Pays : United Kingdom
Organisme : NIDA NIH HHS
ID : R01 DA041336
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Références

Neuropsychopharmacology. 1989 Dec;2(4):299-308
pubmed: 2692589
Brain Res. 1988 Feb 16;441(1-2):111-8
pubmed: 2896049
Stroke. 1995 Apr;26(4):602-5
pubmed: 7709405
Arch Int Pharmacodyn Ther. 1976 May;221(1):105-21
pubmed: 962421
J Neurosci. 1992 Jan;12(1):21-34
pubmed: 1345945
Drug Test Anal. 2018 Feb;10(2):272-283
pubmed: 28513099
Curr Protoc Pharmacol. 2001 May;Chapter 1:Unit 1.20
pubmed: 22293962
Methods Mol Biol. 1999;128:93-102
pubmed: 10320975
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
pubmed: 4202581
Brain Res. 1983 Jan 3;258(1):159-64
pubmed: 24010182
J Pharmacol Exp Ther. 1992 Mar;260(3):1209-13
pubmed: 1312163
Drug Test Anal. 2016 Oct;8(10):1005-1014
pubmed: 26811026
Trends Pharmacol Sci. 2010 Dec;31(12):557-66
pubmed: 20869780
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
J Neurosci Methods. 2007 May 15;162(1-2):346-56
pubmed: 17306885
J Pharmacol Exp Ther. 1999 Feb;288(2):643-52
pubmed: 9918570
Med Chem. 2014;10(8):843-52
pubmed: 24773376
Nature. 1993 Jan 7;361(6407):31-9
pubmed: 8421494
Drug Test Anal. 2014 Jul-Aug;6(7-8):614-32
pubmed: 24678061
Drug Alcohol Depend. 1989 Oct;24(2):95-101
pubmed: 2571492
J Med Chem. 1990 May;33(5):1452-8
pubmed: 2329567
Handb Exp Pharmacol. 2018;252:261-303
pubmed: 30105474
Neuropharmacology. 2017 Jan;112(Pt A):144-149
pubmed: 27520396
Psychopharmacology (Berl). 2001 Jul;156(2-3):117-54
pubmed: 11549216
Anal Bioanal Chem. 2016 Nov;408(29):8467-8481
pubmed: 27744478
J Psychopharmacol. 1992 Jan;6(3):418-24
pubmed: 22291389
Clin Neuropharmacol. 1998 Jan-Feb;21(1):28-34
pubmed: 9579282
Br J Pharmacol. 2015 Sep;172(17):4254-76
pubmed: 26075331
Drug Test Anal. 2016 Jan;8(1):98-109
pubmed: 25873326
Neurochem Int. 2012 Sep;61(4):517-22
pubmed: 22433907
J Neurosci. 2016 Jan 13;36(2):622-31
pubmed: 26758849
PLoS One. 2016 Jun 17;11(6):e0157021
pubmed: 27314670
Psychopharmacology (Berl). 1991;105(2):162-8
pubmed: 1796122
Neuropharmacology. 2018 May 15;134(Pt A):101-107
pubmed: 28807672
Drug Test Anal. 2019 Aug;11(8):1144-1161
pubmed: 31033229
J Anal Toxicol. 2015 May;39(4):287-93
pubmed: 25698777
Pharmacol Res Commun. 1985 May;17(5):471-8
pubmed: 2994123
Psychopharmacology (Berl). 2016 Apr;233(7):1215-25
pubmed: 26758284
Handb Exp Pharmacol. 2018;252:305-352
pubmed: 30196446
Nature. 2012 Dec 13;492(7428):215-20
pubmed: 23235874
Science. 2017 Mar 24;355(6331):
pubmed: 28232581
Neuropharmacology. 2018 Nov;142:30-40
pubmed: 29885421
Mol Psychiatry. 2002;7(8):837-44
pubmed: 12232776
Brain Res Bull. 2001 Nov 15;56(5):495-507
pubmed: 11750795
Drug Test Anal. 2015 May;7(5):358-67
pubmed: 25044512
Eur J Pharmacol. 2018 Jan 15;819:242-247
pubmed: 29225192
Behav Pharmacol. 1999 Feb;10(1):51-62
pubmed: 10780302
J Physiol. 1983 Jan;334:33-46
pubmed: 6306230
Toxicol Lett. 2013 Feb 27;217(2):137-42
pubmed: 23273999
PLoS One. 2014 Feb 28;9(2):e89985
pubmed: 24587167

Auteurs

Jason Wallach (J)

Department of Pharmaceutical Sciences, University of the Sciences, Philadelphia, PA, USA; Substance Use Disorders Institute, University of the Sciences, Philadelphia, PA, USA. Electronic address: j.wallach@usciences.edu.

Tristan Colestock (T)

Department of Pharmaceutical Sciences, University of the Sciences, Philadelphia, PA, USA.

Julià Agramunt (J)

Centre for Synaptic Plasticity, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, United Kingdom.

Matt D B Claydon (MDB)

Centre for Synaptic Plasticity, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, United Kingdom.

Michael Dybek (M)

Department of Chemistry and Biochemistry, University of the Sciences, Philadelphia, PA, USA.

Nadine Filemban (N)

Department of Pharmaceutical Sciences, University of the Sciences, Philadelphia, PA, USA.

Muhammad Chatha (M)

Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.

Adam L Halberstadt (AL)

Department of Psychiatry, University of California San Diego, La Jolla, CA, USA; Research Service, VA San Diego Healthcare System, San Diego, CA, USA.

Simon D Brandt (SD)

School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, United Kingdom.

David Lodge (D)

Centre for Synaptic Plasticity, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, United Kingdom.

Zuner A Bortolotto (ZA)

Centre for Synaptic Plasticity, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, United Kingdom.

Adeboye Adejare (A)

Department of Pharmaceutical Sciences, University of the Sciences, Philadelphia, PA, USA; Department of Chemistry and Biochemistry, University of the Sciences, Philadelphia, PA, USA.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Pharmacological characterizations of the...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Sites de fixation › Pharmacological characterizations of the...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Relation dose-effet des médicaments › Pharmacological characterizations of the...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Transmission synaptique › Potentiels synaptiques › Potentiels post-synaptiques excitateurs › Pharmacological characterizations of the...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Cortex cérébral › Hippocampe › Pharmacological characterizations of the...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes de chimie organique › Isomérie › Pharmacological characterizations of the...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Plasticité neuronale › Potentialisation à long terme › Pharmacological characterizations of the...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrrolidines › Pharmacological characterizations of the...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Pharmacological characterizations of the...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs aux acides aminés › Récepteurs au glutamate › Récepteurs ionotropes du glutamate › Récepteurs du N-méthyl-D-aspartate › Pharmacological characterizations of the...